- Home
- GOSS vs SERA Comparison
GOSS vs SERA Comparison
Compare GOSS & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GOSS | SERA |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.8M | 75.2M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GOSS | SERA |
|---|---|---|
| Price | $0.17 | $1.80 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $4.19 | N/A |
| AVG Volume (30 Days) | ★ 15.1M | 44.9K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.32 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $48,471,000.00 | $81,000.00 |
| Revenue This Year | N/A | $554.81 |
| Revenue Next Year | $201.64 | $517.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.19 |
| 52 Week Low | $0.14 | $1.56 |
| 52 Week High | $3.87 | $4.09 |
Technical Indicators
Market Signals| Indicator | GOSS | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 34.86 | 43.98 |
| Support Level | $0.16 | $1.61 |
| Resistance Level | $0.36 | $2.40 |
| Average True Range (ATR) | 0.02 | 0.17 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 47.73 | 19.01 |
Price Performance
Historical ComparisonAbout GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.